Expectations for 2017 Results, page-2

First 2 Last

Share
Profile

Follow
TheSparkGuy

1,434 Posts.

20

07/08/17

09:18

Post #: 26327820
Share

Originally posted by Kiwoz48 ↑

Anyone thinking about what the 2017 results might look like?

My view is that both revenues and profit figures will be higher than consensus. My basic model projects that:
a) the MNY loan book has been growing more strongly than (it seems) others are assuming, and
b) management still have the clamps tightly on costs.

My projections for the financial year are:
The balance of the gross loan book will be £281m, up $72m from June 2016 and $34m from Dec 2017.
Revenue = $113,5m, up $16.8m (+17%)
Total costs = $68m, up just $1m (+1.5%)
Profit before tax = $45.2m, up $15.8m (+54%)
NPAT = $31.3m, up $11m (+56%)
EPS = 20.0 cents
Final dividend = 3.2cents

As a comparison to my arguably amateurish numbers, the current '4-traders' projections for 2017 are:
Revenue $107m
EPS = 18.2 cents
Final Dividend = 2.5 cents

If I am right(ish) then these results will catch the market by surprise and the results will catapult the SP to well above $2.00. And also, the larger loan book in 2017 will be sufficient to generate an EPS of about 26 cents in 2018, a figure that is around 30% above current consensus.

Anyone know of any reason why I am wrong? Be pleased to hear from you.

K

Expand

MNY is my 2nd largest holding.

I love the sound of your numbers but at the end of May they reaffirmed NPAT guidance at $27.5m. Its hard to see them overshooting to 31.3m with just one month more trading.

The cost out story will continue with the closure of shopfronts.

MNY Price at posting: $1.47 Sentiment: Buy Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025

WC8

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

ACW

This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game

MIN

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

Chaos reigns markets – so let's take stock of where we're at ahead of December

There are more pages in this discussion • 11 more messages in this thread...

First 2 Last

Add MNY (ASX) to my watchlist

Expectations for 2017 Results, page-2

Top Stories

History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

Chaos reigns markets – so let's take stock of where we're at ahead of December